UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Toxicological sciences, 2017-01, Vol.155 (1), p.61-74

2017

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial

Journal of clinical pharmacology, 2017-07, Vol.57 (7), p.906-917

2017

Volltextzugriff (PDF)

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non‐peptide AVP antagonist in healthy subjects

British journal of clinical pharmacology, 2012-04, Vol.73 (4), p.579-587

2012

Volltextzugriff (PDF)

Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters

Clinical and translational science, 2021-07, Vol.14 (4), p.1535-1542

2021

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects

European journal of clinical pharmacology, 2012-12, Vol.68 (12), p.1595-1603

2012

Volltextzugriff (PDF)

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4

Kidney international reports, 2017-11, Vol.2 (6), p.1132-1140

2017

Volltextzugriff (PDF)

In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects

Journal of clinical pharmacology, 2011-05, Vol.51 (5), p.761-769

2011

Volltextzugriff (PDF)

Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults

European journal of clinical pharmacology, 2017-11, Vol.73 (11), p.1399-1408

2017

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function

Kidney international, 2014-04, Vol.85 (4), p.953-961

2014

Volltextzugriff (PDF)

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects

Antimicrobial agents and chemotherapy, 2016-10, Vol.60 (10), p.5976-5985

2016

Volltextzugriff (PDF)

Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects

International journal of clinical pharmacology and therapeutics, 2012-02, Vol.50 (2), p.150-156

2012

Volltextzugriff (PDF)

Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Journal of clinical pharmacology, 2019-05, Vol.59 (5), p.763-770

2019

Volltextzugriff (PDF)

A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials

Clinical journal of the American Society of Nephrology, 2020-05, Vol.15 (5), p.643-650

2020

Volltextzugriff (PDF)

Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial

Clinical journal of the American Society of Nephrology, 2023-01, Vol.18 (1), p.36-46

2023

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan, a Non-Peptide AVP Antagonist, and Furosemide or Hydrochlorothiazide

Journal of cardiovascular pharmacology, 2007-08, Vol.50 (2), p.213-222

2007

Volltextzugriff (PDF)

Effects of Hepatic or Renal Impairment on the Pharmacokinetics of Aripiprazole

Clinical pharmacokinetics, 2008-01, Vol.47 (8), p.533-542

2008

Volltextzugriff (PDF)

Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial

European journal of pediatrics, 2019-07, Vol.178 (7), p.1013-1021

2019

Volltextzugriff (PDF)

Comparing Effects of Tolvaptan and Instruction to Increase Water Consumption in ADPKD: Post Hoc Analysis of TEMPO 3:4

Kidney360, 2023-12, Vol.4 (12), p.1702-1707

2023

Volltextzugriff (PDF)

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease

Kidney international, 2013-12, Vol.84 (6), p.1278-1286

2013

Volltextzugriff (PDF)

Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults

Journal of psychopharmacology (Oxford), 2023-02, Vol.37 (2), p.164-171

2023

Volltextzugriff (PDF)

Effects of Desipramine, Amitriptyline, and Fluoxetine on Pain in Diabetic Neuropathy

The New England journal of medicine, 1992-05, Vol.326 (19), p.1250-1256

1992

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan and Warfarin in Healthy Subjects

Clinical pharmacology in drug development, 2012-04, Vol.1 (2), p.67-75

2012

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Safety of Tolvaptan, a Nonpeptide AVP Antagonist, During Ascending Single-Dose Studies in Healthy Subjects

Journal of clinical pharmacology, 2007-12, Vol.47 (12), p.1498-1507

2007

Volltextzugriff (PDF)

Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects

European journal of clinical pharmacology, 2012-02, Vol.68 (2), p.207-211

2012

Volltextzugriff (PDF)

The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations

Kidney international reports, 2020-06, Vol.5 (6), p.801-812

2020

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(73)
Bücher
(1)

Sprache

Englisch
(74)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(53)
Science & Technology
(53)
Male
(43)
Humans
(39)
Pharmacology & Pharmacy
(29)
Adult
(26)
Female
(26)
Biological And Medical Sciences
(24)
Medical Sciences
(20)
Tolvaptan
(20)
Middle Aged
(18)
Pharmacokinetics
(17)
Animals
(15)
Pharmacodynamics
(15)
Benzazepines - Pharmacokinetics
(13)
Adolescent
(10)
Antidiuretic Hormone Receptor Antagonists
(10)
Hydroxyindoleacetic Acid - Cerebrospinal Fluid
(9)
Pharmacology. Drug Treatments
(9)
Young Adult
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non‐peptide AVP antagonist in healthy subjects

Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters

Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4

In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects

Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects

Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects

Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials

Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial

Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan, a Non-Peptide AVP Antagonist, and Furosemide or Hydrochlorothiazide

Effects of Hepatic or Renal Impairment on the Pharmacokinetics of Aripiprazole

Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial

Comparing Effects of Tolvaptan and Instruction to Increase Water Consumption in ADPKD: Post Hoc Analysis of TEMPO 3:4

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease

Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults

Effects of Desipramine, Amitriptyline, and Fluoxetine on Pain in Diabetic Neuropathy

Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan and Warfarin in Healthy Subjects

Pharmacokinetics, Pharmacodynamics, and Safety of Tolvaptan, a Nonpeptide AVP Antagonist, During Ascending Single-Dose Studies in Healthy Subjects

Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects

The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations

Suchergebnisse filtern